Nicholas Dcunha
Hematology & Oncology · Lubbock, TXNPI 1104815802
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (34.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 22.7%. Reporting peaked in 2019 at $7,433 and has fallen 52.6% since, to $3,523 in 2024.
Across 131 payments — averaging $182.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$5K
- Pharmacosmos Therapeutics Inc.$5K
- Incyte Corporation$4K
- Karyopharm Therapeutics Inc.$2K
- Epizyme, Inc.$2K
- Astellas Pharma US Inc$817
- plus $4K from 26 others
Across 5 payments — averaging $4547.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$23K
What the payments were for
- Consulting fees$7,10030%
- Speaking & faculty fees$8,25535%
- Travel & lodging$3,35514%
- Food & beverage$4,64219%
- Education$5262%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 15 | $5,411 |
| Pharmacosmos Therapeutics Inc. | 7 | $5,372 |
| Incyte Corporation | 8 | $3,773 |
| Karyopharm Therapeutics Inc. | 1 | $2,325 |
| Epizyme, Inc. | 2 | $2,105 |
| Astellas Pharma US Inc | 8 | $817 |
| AstraZeneca(2 entities) | 14 | $562 |
| Daiichi Sankyo Inc. | 1 | $360 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $317 |
| Seagen Inc. | 5 | $295 |
| Genentech USA, Inc. | 7 | $292 |
| Amgen | 10 | $274 |
| Jazz Pharmaceuticals Inc. | 2 | $198 |
| Sanofi | 3 | $189 |
| Merck | 9 | $144 |
| AbbVie | 2 | $144 |
| Exelixis Inc. | 3 | $128 |
| E.r. Squibb & Sons, L.L.C. | 5 | $125 |
| Apellis Pharmaceuticals, Inc. | 1 | $125 |
| Novocure Inc. | 1 | $112 |
| Janssen Scientific Affairs, LLC | 1 | $109 |
| Tersera Therapeutics LLC | 4 | $108 |
| Novartis | 5 | $107 |
| Bristol Myers Squibb | 1 | $95 |
| Otsuka America Pharmaceutical, Inc. | 1 | $94 |
| Array Biopharma Inc | 1 | $87 |
| Pfizer | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $53 |
| Eisai Inc. | 2 | $41 |
| Taiho Oncology, Inc. | 2 | $23 |
| Bayer | 1 | $18 |
| Rigel Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,877 in reported general payments places this provider in the 80th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Lubbock
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.